Business
Medicenna Announces Presentations at the 2017 Annual Meeting of the Society of Neuro-Oncology
Medicenna Announces Presentations at the 2017 Annual Meeting of the Society of Neuro-Oncol...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Announces Presentations at the 2017 Annual Meeting of the Society of Neuro-Oncology\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-BOTTOM:1pt; BORDER-LEFT:1pt; PADDING-LEFT:0.50em; PADDING-RIGHT:0.50em; BORDER-TOP:1pt; BORDER-RIGHT:1pt\n}\n.prntblns{\nBORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt\n}\n.prnsbb1{\nBORDER-BOTTOM:1pt\n}\n.prnsbr1{\nBORDER-RIGHT:1pt\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnsbl1{\nBORDER-LEFT:1pt\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnsbt1{\nBORDER-TOP:1pt\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prnvat{\nVERTICAL-ALIGN: TOP\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, TX, Nov. 9, 2017\n\n\n\nPresentations Will Provide Updates on Drug Distribution and Safety Results\n\n\n\nTORONTO and HOUSTON, TX, Nov. 9, 2017 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA; OTCQX: MDNAF), a clinical stage immuno-oncology company, today announced that Dr. Krystof Bankiewicz, MD, PhD, Kinetics Foundation Chair in Translational Research and Professor in Residence of Neurological Surgery at the University of California San Francisco, will present early results from the on-going clinical trial of the Company's targeted immunotherapy, MDNA55, at the 22nd Annual Meeting of the Society of Neuro-Oncology (\"SNO\") to be held from November 15-19, 2017 in San Francisco, CA.\n\nThe oral and poster presentations by Dr. Bankiewicz will provide an update on drug distribution and safety data from the MDNA55 Phase 2b clinical trial in patients with recurrent glioblastoma (rGBM), the most common and deadly form of brain cancer. \n\nThe details of the presentations are as follows:\n\n\n\n\nTitle:         \n\n\nClinical Trials of Direct Delivery of Gliomas: Update on the MDNA55 Program\n\n\n\nDate:\n\n\nWednesday, November 15, 2017\n\n\n\nTime:\n\n\nOral Presentation: 10:25 – 10:45 am\n\n\n\nSession:\n\n\nThe 2017 SNO-SCIDOT Conference on Therapeutic Delivery to the Central...